Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical Clinical Trials Platform Technologies

Auxilium Pharmaceuticals Inc.

This article was originally published in Start Up

  • Heather Slowik

Executive Summary

Entrepreneurs seeking to fund product-focused businesses during the height of the biotech financing boom faced an uphill battle. "Everybody wanted to invest in rocket science in the middle of 2000," notes Gerri Henwood, president, CEO, and founder of Auxilium Pharmaceuticals Inc. Many VCs questioned Auxilium's mission to develop enhanced products for male hormone replacement therapy (HRT). Despite this initial resistance, Henwood persevered, and her comparatively low-risk company garnered increasing VC attention as it breezed through clinical trials on its first product.

Table

View full table

Topics

Related Companies

Related Deals

Tags:
BioPharmaceutical Clinical Trials Platform Technologies
Latest Headlines

BridgeBio Spins Out Cancer Arm With $200m Fundraise

Emergex Goes To Battle Against ‘The Nasties’

Finance Watch: Venture Rounds Trend Toward The High End

The UK’s Cancer Vaccine Partnership With BioNTech Is Another First – But Can It Deliver?

See All
UsernamePublicRestriction

Register

SC090724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By